Total submissions: 1
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Ambry Genetics | RCV004291497 | SCV003946660 | uncertain significance | not specified | 2023-03-20 | criteria provided, single submitter | clinical testing | The c.61C>A (p.Q21K) alteration is located in exon 3 (coding exon 1) of the SLC14A1 gene. This alteration results from a C to A substitution at nucleotide position 61, causing the glutamine (Q) at amino acid position 21 to be replaced by a lysine (K). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |